Camp4 Therapeutics (CAMP) Cash from Financing Activities (2023 - 2026)
Camp4 Therapeutics (CAMP) reported Cash from Financing Activities of $57000.0 for Q1 2026, up 137.75% on a YoY basis from $23974.9 in Q1 2025, and down 99.8% sequentially from $28.6 million in Q4 2025.
Camp4 Therapeutics (CAMP) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Camp4 Therapeutics (CAMP) has 4 years of Cash from Financing Activities data on file, last reported at $57000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 137.75% year-over-year to $57000.0; the trailing twelve-month figure through Mar 2026 stood at $76.1 million (up 6.11% YoY), and the FY2025 full-year result was $75.9 million, up 5.9% from the prior year.
- Cash from Financing Activities declined to $57000.0 in Q1 2026, from $28.6 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $73.1 million in Q4 2024 to a low of -$812000.0 in Q2 2024.
- A 4-year average of $14.8 million and a median of -$3000.0 in 2023 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities surged 116071.43% in 2024 and plunged 60.88% in 2025, its largest moves.
- Tracing CAMP's Cash from Financing Activities over 4 years: stood at -$63000.0 in 2023, then surged by 116071.43% to $73.1 million in 2024, then sank by 60.88% to $28.6 million in 2025, then tumbled by 99.8% to $57000.0 in 2026.
- Business Quant data shows CAMP's Cash from Financing Activities at $57000.0 in Q1 2026, $28.6 million in Q4 2025, and $47.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Camp4 Therapeutics | 174.35 Mn | 174.35 Mn | - | 57,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57,000.00 |
| Mar 31, 2026 | 57,000.00 |
| Dec 31, 2025 | 28.59 Mn |
| Dec 31, 2025 | 28.59 Mn |
| Sep 30, 2025 | 47.38 Mn |
| Sep 30, 2025 | 47.38 Mn |
| Jun 30, 2025 | 72,000.00 |
| Jun 30, 2025 | 72,000.00 |
| Mar 31, 2025 | -151,000.00 |
| Mar 31, 2025 | -151,000.00 |
| Dec 31, 2024 | 73.06 Mn |
| Dec 31, 2024 | 73.06 Mn |
| Sep 30, 2024 | -386,000.00 |
| Sep 30, 2024 | -386,000.00 |
| Jun 30, 2024 | -812,000.00 |
| Jun 30, 2024 | -812,000.00 |
| Mar 31, 2024 | -202,000.00 |
| Mar 31, 2024 | -202,000.00 |
| Dec 31, 2023 | -63,000.00 |
| Dec 31, 2023 | -63,000.00 |